APO Research
Talk to an analyst

APO RESEARCH · REPORT

Medications for Chronic Pain Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Medications for Chronic Pain Treatment Market Analysis and Forecast 2026-2032

22 December 2025207 pages

Choose your research edition.

Industry ResearchMedications for Chronic Pain Treatment Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Medications for Chronic Pain Treatment Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Medications for Chronic Pain Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medications for Chronic Pain Treatment Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Medications for Chronic Pain Treatment Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Medications for Chronic Pain Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Medications for Chronic Pain Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Medications for Chronic Pain Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Medications for Chronic Pain Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Medications for Chronic Pain Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Medications for Chronic Pain Treatment include YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD., Southwest Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., REYOUNG, Johnson and Johnson Services Inc., Novartis AG, Merck & Co., Jiangsu Hengrui Medicine Co,.Ltd and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Medications for Chronic Pain Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Medications for Chronic Pain Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Medications for Chronic Pain Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Medications for Chronic Pain Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Medications for Chronic Pain Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Medications for Chronic Pain Treatment revenue, projected growth trends, production technology, application and end-user industry.

Medications for Chronic Pain Treatment Segment by Company

YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.

Southwest Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Ltd.

REYOUNG

Johnson and Johnson Services Inc.

Novartis AG

Merck & Co.

Jiangsu Hengrui Medicine Co,.Ltd

Pfizer

GlaxoSmithKline plc.

BAYER

AstraZeneca plc.

Purdue Pharma L.P.

Endo International plc.

Depomed

Abbott Laboratories

Medications for Chronic Pain Treatment Segment by Type

Nonopioid

Opioids

Medications for Chronic Pain Treatment Segment by Application

Hospital

Pharmacy

Other

Medications for Chronic Pain Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medications for Chronic Pain Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medications for Chronic Pain Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medications for Chronic Pain Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Medications for Chronic Pain Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Medications for Chronic Pain Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Medications for Chronic Pain Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Medications for Chronic Pain Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Nonopioid Major Player Table 3. Opioids Major Player Table 4. Global Medications for Chronic Pain Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Pharmacy Major Player Table 7. Other Major Player Table 8. Medications for Chronic Pain Treatment Industry Trends Table 9. Medications for Chronic Pain Treatment Industry Drivers Table 10. Medications for Chronic Pain Treatment Industry Opportunities and Challenges Table 11. Medications for Chronic Pain Treatment Industry Restraints Table 12. Global Medications for Chronic Pain Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Medications for Chronic Pain Treatment Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Medications for Chronic Pain Treatment Market Share by Region (2021-2026) Table 15. Global Medications for Chronic Pain Treatment Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Medications for Chronic Pain Treatment Market Share by Region (2027-2032) Table 17. Global Medications for Chronic Pain Treatment Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Medications for Chronic Pain Treatment Revenue Market Share by Players (2021-2026) Table 19. Global Medications for Chronic Pain Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Medications for Chronic Pain Treatment Key Players Headquarters & Area Served Table 21. Global Medications for Chronic Pain Treatment Players, Product Type & Application Table 22. Global Medications for Chronic Pain Treatment Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Medications for Chronic Pain Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Medications for Chronic Pain Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Medications for Chronic Pain Treatment Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Medications for Chronic Pain Treatment Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Medications for Chronic Pain Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Medications for Chronic Pain Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Medications for Chronic Pain Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Medications for Chronic Pain Treatment Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Medications for Chronic Pain Treatment Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Medications for Chronic Pain Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Medications for Chronic Pain Treatment Revenue Market Share by Application (2027-2032) Table 35. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Company Information Table 36. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Business Overview Table 37. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Product Portfolio Table 39. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Recent Development Table 40. Southwest Pharmaceutical Co., Ltd. Company Information Table 41. Southwest Pharmaceutical Co., Ltd. Business Overview Table 42. Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Product Portfolio Table 44. Southwest Pharmaceutical Co., Ltd. Recent Development Table 45. Teva Pharmaceutical Industries Ltd. Company Information Table 46. Teva Pharmaceutical Industries Ltd. Business Overview Table 47. Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Product Portfolio Table 49. Teva Pharmaceutical Industries Ltd. Recent Development Table 50. REYOUNG Company Information Table 51. REYOUNG Business Overview Table 52. REYOUNG Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. REYOUNG Medications for Chronic Pain Treatment Product Portfolio Table 54. REYOUNG Recent Development Table 55. Johnson and Johnson Services Inc. Company Information Table 56. Johnson and Johnson Services Inc. Business Overview Table 57. Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Product Portfolio Table 59. Johnson and Johnson Services Inc. Recent Development Table 60. Novartis AG Company Information Table 61. Novartis AG Business Overview Table 62. Novartis AG Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Novartis AG Medications for Chronic Pain Treatment Product Portfolio Table 64. Novartis AG Recent Development Table 65. Merck & Co. Company Information Table 66. Merck & Co. Business Overview Table 67. Merck & Co. Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Merck & Co. Medications for Chronic Pain Treatment Product Portfolio Table 69. Merck & Co. Recent Development Table 70. Jiangsu Hengrui Medicine Co,.Ltd Company Information Table 71. Jiangsu Hengrui Medicine Co,.Ltd Business Overview Table 72. Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Product Portfolio Table 74. Jiangsu Hengrui Medicine Co,.Ltd Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Pfizer Medications for Chronic Pain Treatment Product Portfolio Table 79. Pfizer Recent Development Table 80. GlaxoSmithKline plc. Company Information Table 81. GlaxoSmithKline plc. Business Overview Table 82. GlaxoSmithKline plc. Medications for Chronic Pain Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. GlaxoSmithKline plc. Medications for Chronic Pain Treatment Product Portfolio Table 84. GlaxoSmithKline plc. Recent Development Table 85. BAYER Company Information Table 86. BAYER Business Overview Table 87. BAYER Medications for Chronic Pain Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. BAYER Medications for Chronic Pain Treatment Product Portfolio Table 89. BAYER Recent Development Table 90. AstraZeneca plc. Company Information Table 91. AstraZeneca plc. Business Overview Table 92. AstraZeneca plc. Medications for Chronic Pain Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. AstraZeneca plc. Medications for Chronic Pain Treatment Product Portfolio Table 94. AstraZeneca plc. Recent Development Table 95. Purdue Pharma L.P. Company Information Table 96. Purdue Pharma L.P. Business Overview Table 97. Purdue Pharma L.P. Medications for Chronic Pain Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Purdue Pharma L.P. Medications for Chronic Pain Treatment Product Portfolio Table 99. Purdue Pharma L.P. Recent Development Table 100. Endo International plc. Company Information Table 101. Endo International plc. Business Overview Table 102. Endo International plc. Medications for Chronic Pain Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Endo International plc. Medications for Chronic Pain Treatment Product Portfolio Table 104. Endo International plc. Recent Development Table 105. Depomed Company Information Table 106. Depomed Business Overview Table 107. Depomed Medications for Chronic Pain Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Depomed Medications for Chronic Pain Treatment Product Portfolio Table 109. Depomed Recent Development Table 110. Abbott Laboratories Company Information Table 111. Abbott Laboratories Business Overview Table 112. Abbott Laboratories Medications for Chronic Pain Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Abbott Laboratories Medications for Chronic Pain Treatment Product Portfolio Table 114. Abbott Laboratories Recent Development Table 115. North America Medications for Chronic Pain Treatment Revenue by Type (2021-2026) & (US$ Million) Table 116. North America Medications for Chronic Pain Treatment Revenue by Type (2027-2032) & (US$ Million) Table 117. North America Medications for Chronic Pain Treatment Revenue by Application (2021-2026) & (US$ Million) Table 118. North America Medications for Chronic Pain Treatment Revenue by Application (2027-2032) & (US$ Million) Table 119. North America Medications for Chronic Pain Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Medications for Chronic Pain Treatment Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Medications for Chronic Pain Treatment Revenue by Country (US$ Million) & (2027-2032) Table 122. Europe Medications for Chronic Pain Treatment Revenue by Type (2021-2026) & (US$ Million) Table 123. Europe Medications for Chronic Pain Treatment Revenue by Type (2027-2032) & (US$ Million) Table 124. Europe Medications for Chronic Pain Treatment Revenue by Application (2021-2026) & (US$ Million) Table 125. Europe Medications for Chronic Pain Treatment Revenue by Application (2027-2032) & (US$ Million) Table 126. Europe Medications for Chronic Pain Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Europe Medications for Chronic Pain Treatment Revenue by Country (2021-2026) & (US$ Million) Table 128. Europe Medications for Chronic Pain Treatment Revenue by Country (US$ Million) & (2027-2032) Table 129. China Medications for Chronic Pain Treatment Revenue by Type (2021-2026) & (US$ Million) Table 130. China Medications for Chronic Pain Treatment Revenue by Type (2027-2032) & (US$ Million) Table 131. China Medications for Chronic Pain Treatment Revenue by Application (2021-2026) & (US$ Million) Table 132. China Medications for Chronic Pain Treatment Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Medications for Chronic Pain Treatment Revenue by Type (2021-2026) & (US$ Million) Table 134. Asia Medications for Chronic Pain Treatment Revenue by Type (2027-2032) & (US$ Million) Table 135. Asia Medications for Chronic Pain Treatment Revenue by Application (2021-2026) & (US$ Million) Table 136. Asia Medications for Chronic Pain Treatment Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia Medications for Chronic Pain Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Asia Medications for Chronic Pain Treatment Revenue by Region (US$ Million) & (2021-2026) Table 139. Asia Medications for Chronic Pain Treatment Revenue by Region (US$ Million) & (2027-2032) Table 140. SAMEA Medications for Chronic Pain Treatment Revenue by Type (2021-2026) & (US$ Million) Table 141. SAMEA Medications for Chronic Pain Treatment Revenue by Type (2027-2032) & (US$ Million) Table 142. SAMEA Medications for Chronic Pain Treatment Revenue by Application (2021-2026) & (US$ Million) Table 143. SAMEA Medications for Chronic Pain Treatment Revenue by Application (2027-2032) & (US$ Million) Table 144. SAMEA Medications for Chronic Pain Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. SAMEA Medications for Chronic Pain Treatment Revenue by Country (2021-2026) & (US$ Million) Table 146. SAMEA Medications for Chronic Pain Treatment Revenue by Country (US$ Million) & (2027-2032) Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Medications for Chronic Pain Treatment Image Figure 2. Global Medications for Chronic Pain Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medications for Chronic Pain Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Nonopioid Image Figure 5. Opioids Image Figure 6. Global Medications for Chronic Pain Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Medications for Chronic Pain Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Medications for Chronic Pain Treatment Market Size (US$ Million) & (2021-2032) Figure 12. Global Medications for Chronic Pain Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Medications for Chronic Pain Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Medications for Chronic Pain Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Medications for Chronic Pain Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Medications for Chronic Pain Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Medications for Chronic Pain Treatment Revenue Market Share by Type (2021-2032) Figure 19. Global Medications for Chronic Pain Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Medications for Chronic Pain Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Medications for Chronic Pain Treatment Revenue Market Share by Application (2021-2032) Figure 22. North America Medications for Chronic Pain Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032) Figure 24. North America Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032) Figure 25. North America Medications for Chronic Pain Treatment Revenue Share by Country (2021-2032) Figure 26. United States Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Medications for Chronic Pain Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032) Figure 31. Europe Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032) Figure 32. Europe Medications for Chronic Pain Treatment Revenue Share by Country (2021-2032) Figure 33. Germany Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Medications for Chronic Pain Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032) Figure 43. China Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032) Figure 44. Asia Medications for Chronic Pain Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032) Figure 46. Asia Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Medications for Chronic Pain Treatment Revenue Share by Region (2021-2032) Figure 48. Japan Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Medications for Chronic Pain Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032) Figure 56. SAMEA Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032) Figure 57. SAMEA Medications for Chronic Pain Treatment Revenue Share by Country (2021-2032) Figure 58. Brazil Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Medications for Chronic Pain Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Nonopioid
  • Opioids
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.
  • Southwest Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • REYOUNG
  • Johnson and Johnson Services Inc.
  • Novartis AG
  • Merck & Co.
  • Jiangsu Hengrui Medicine Co,.Ltd
  • Pfizer
  • GlaxoSmithKline plc.
  • BAYER
  • AstraZeneca plc.
  • Purdue Pharma L.P.
  • Endo International plc.
  • Depomed
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Medications for Chronic Pain Treatment Market by Type
  3. 1.2.1 Global Medications for Chronic Pain Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Nonopioid
  5. 1.2.3 Opioids
  6. 1.3 Medications for Chronic Pain Treatment Market by Application
  7. 1.3.1 Global Medications for Chronic Pain Treatment Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Medications for Chronic Pain Treatment Market Dynamics
  1. 2.1 Medications for Chronic Pain Treatment Industry Trends
  2. 2.2 Medications for Chronic Pain Treatment Industry Drivers
  3. 2.3 Medications for Chronic Pain Treatment Industry Opportunities and Challenges
  4. 2.4 Medications for Chronic Pain Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Medications for Chronic Pain Treatment Market Perspective (2021-2032)
  2. 3.2 Global Medications for Chronic Pain Treatment Growth Trends by Region
  3. 3.2.1 Global Medications for Chronic Pain Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Medications for Chronic Pain Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Medications for Chronic Pain Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Medications for Chronic Pain Treatment Revenue by Players
  2. 4.1.1 Global Medications for Chronic Pain Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Medications for Chronic Pain Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Medications for Chronic Pain Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Medications for Chronic Pain Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Medications for Chronic Pain Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Medications for Chronic Pain Treatment Players, Product Type & Application
  8. 4.5 Global Medications for Chronic Pain Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Medications for Chronic Pain Treatment Market CR5 and HHI
  11. 4.6.3 2025 Medications for Chronic Pain Treatment Tier 1, Tier 2, and Tier 3
5 Medications for Chronic Pain Treatment Market Size by Type
  1. 5.1 Global Medications for Chronic Pain Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Medications for Chronic Pain Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Medications for Chronic Pain Treatment Revenue Market Share by Type (2021-2032)
6 Medications for Chronic Pain Treatment Market Size by Application
  1. 6.1 Global Medications for Chronic Pain Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Medications for Chronic Pain Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Medications for Chronic Pain Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.
  2. 7.1.1 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Company Information
  3. 7.1.2 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Business Overview
  4. 7.1.3 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Medications for Chronic Pain Treatment Product Portfolio
  6. 7.1.5 YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. Recent Developments
  7. 7.2 Southwest Pharmaceutical Co., Ltd.
  8. 7.2.1 Southwest Pharmaceutical Co., Ltd. Company Information
  9. 7.2.2 Southwest Pharmaceutical Co., Ltd. Business Overview
  10. 7.2.3 Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Southwest Pharmaceutical Co., Ltd. Medications for Chronic Pain Treatment Product Portfolio
  12. 7.2.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
  13. 7.3 Teva Pharmaceutical Industries Ltd.
  14. 7.3.1 Teva Pharmaceutical Industries Ltd. Company Information
  15. 7.3.2 Teva Pharmaceutical Industries Ltd. Business Overview
  16. 7.3.3 Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Teva Pharmaceutical Industries Ltd. Medications for Chronic Pain Treatment Product Portfolio
  18. 7.3.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  19. 7.4 REYOUNG
  20. 7.4.1 REYOUNG Company Information
  21. 7.4.2 REYOUNG Business Overview
  22. 7.4.3 REYOUNG Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 REYOUNG Medications for Chronic Pain Treatment Product Portfolio
  24. 7.4.5 REYOUNG Recent Developments
  25. 7.5 Johnson and Johnson Services Inc.
  26. 7.5.1 Johnson and Johnson Services Inc. Company Information
  27. 7.5.2 Johnson and Johnson Services Inc. Business Overview
  28. 7.5.3 Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Johnson and Johnson Services Inc. Medications for Chronic Pain Treatment Product Portfolio
  30. 7.5.5 Johnson and Johnson Services Inc. Recent Developments
  31. 7.6 Novartis AG
  32. 7.6.1 Novartis AG Company Information
  33. 7.6.2 Novartis AG Business Overview
  34. 7.6.3 Novartis AG Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis AG Medications for Chronic Pain Treatment Product Portfolio
  36. 7.6.5 Novartis AG Recent Developments
  37. 7.7 Merck & Co.
  38. 7.7.1 Merck & Co. Company Information
  39. 7.7.2 Merck & Co. Business Overview
  40. 7.7.3 Merck & Co. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck & Co. Medications for Chronic Pain Treatment Product Portfolio
  42. 7.7.5 Merck & Co. Recent Developments
  43. 7.8 Jiangsu Hengrui Medicine Co,.Ltd
  44. 7.8.1 Jiangsu Hengrui Medicine Co,.Ltd Company Information
  45. 7.8.2 Jiangsu Hengrui Medicine Co,.Ltd Business Overview
  46. 7.8.3 Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Jiangsu Hengrui Medicine Co,.Ltd Medications for Chronic Pain Treatment Product Portfolio
  48. 7.8.5 Jiangsu Hengrui Medicine Co,.Ltd Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Medications for Chronic Pain Treatment Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 GlaxoSmithKline plc.
  56. 7.10.1 GlaxoSmithKline plc. Company Information
  57. 7.10.2 GlaxoSmithKline plc. Business Overview
  58. 7.10.3 GlaxoSmithKline plc. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GlaxoSmithKline plc. Medications for Chronic Pain Treatment Product Portfolio
  60. 7.10.5 GlaxoSmithKline plc. Recent Developments
  61. 7.11 BAYER
  62. 7.11.1 BAYER Company Information
  63. 7.11.2 BAYER Business Overview
  64. 7.11.3 BAYER Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 BAYER Medications for Chronic Pain Treatment Product Portfolio
  66. 7.11.5 BAYER Recent Developments
  67. 7.12 AstraZeneca plc.
  68. 7.12.1 AstraZeneca plc. Company Information
  69. 7.12.2 AstraZeneca plc. Business Overview
  70. 7.12.3 AstraZeneca plc. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AstraZeneca plc. Medications for Chronic Pain Treatment Product Portfolio
  72. 7.12.5 AstraZeneca plc. Recent Developments
  73. 7.13 Purdue Pharma L.P.
  74. 7.13.1 Purdue Pharma L.P. Company Information
  75. 7.13.2 Purdue Pharma L.P. Business Overview
  76. 7.13.3 Purdue Pharma L.P. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Purdue Pharma L.P. Medications for Chronic Pain Treatment Product Portfolio
  78. 7.13.5 Purdue Pharma L.P. Recent Developments
  79. 7.14 Endo International plc.
  80. 7.14.1 Endo International plc. Company Information
  81. 7.14.2 Endo International plc. Business Overview
  82. 7.14.3 Endo International plc. Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Endo International plc. Medications for Chronic Pain Treatment Product Portfolio
  84. 7.14.5 Endo International plc. Recent Developments
  85. 7.15 Depomed
  86. 7.15.1 Depomed Company Information
  87. 7.15.2 Depomed Business Overview
  88. 7.15.3 Depomed Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Depomed Medications for Chronic Pain Treatment Product Portfolio
  90. 7.15.5 Depomed Recent Developments
  91. 7.16 Abbott Laboratories
  92. 7.16.1 Abbott Laboratories Company Information
  93. 7.16.2 Abbott Laboratories Business Overview
  94. 7.16.3 Abbott Laboratories Medications for Chronic Pain Treatment Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Abbott Laboratories Medications for Chronic Pain Treatment Product Portfolio
  96. 7.16.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Medications for Chronic Pain Treatment Revenue (2021-2032)
  2. 8.2 North America Medications for Chronic Pain Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Medications for Chronic Pain Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Medications for Chronic Pain Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Medications for Chronic Pain Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Medications for Chronic Pain Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Medications for Chronic Pain Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Medications for Chronic Pain Treatment Revenue by Country
  11. 8.6.1 North America Medications for Chronic Pain Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Medications for Chronic Pain Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Medications for Chronic Pain Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Medications for Chronic Pain Treatment Revenue (2021-2032)
  2. 9.2 Europe Medications for Chronic Pain Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Medications for Chronic Pain Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Medications for Chronic Pain Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Medications for Chronic Pain Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Medications for Chronic Pain Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Medications for Chronic Pain Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Medications for Chronic Pain Treatment Revenue by Country
  11. 9.6.1 Europe Medications for Chronic Pain Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Medications for Chronic Pain Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Medications for Chronic Pain Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Medications for Chronic Pain Treatment Revenue (2021-2032)
  2. 10.2 China Medications for Chronic Pain Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Medications for Chronic Pain Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Medications for Chronic Pain Treatment Revenue by Type (2027-2032)
  5. 10.3 China Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Medications for Chronic Pain Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Medications for Chronic Pain Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Medications for Chronic Pain Treatment Revenue by Application (2027-2032)
  9. 10.5 China Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Medications for Chronic Pain Treatment Revenue (2021-2032)
  2. 11.2 Asia Medications for Chronic Pain Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Medications for Chronic Pain Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Medications for Chronic Pain Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Medications for Chronic Pain Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Medications for Chronic Pain Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Medications for Chronic Pain Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Medications for Chronic Pain Treatment Revenue by Country
  11. 11.6.1 Asia Medications for Chronic Pain Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Medications for Chronic Pain Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Medications for Chronic Pain Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Medications for Chronic Pain Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Medications for Chronic Pain Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Medications for Chronic Pain Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Medications for Chronic Pain Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Medications for Chronic Pain Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Medications for Chronic Pain Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Medications for Chronic Pain Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Medications for Chronic Pain Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Medications for Chronic Pain Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Medications for Chronic Pain Treatment Revenue by Country
  11. 12.6.1 SAMEA Medications for Chronic Pain Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Medications for Chronic Pain Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Medications for Chronic Pain Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst